200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Reports Second Quarter 2026 Financials
New Manufacturing Agreement with Alivus Life Sciences for Crofelemer
Other Events
Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Announces Plan to Explore Strategic Alternatives to Align with Targeted NDA for Rare Disease Intestinal Failure
Amended material disclosure
Jaguar Health, Inc. Enters Royalty Interest Amendments with Uptown Capital
Jaguar Health Enters $40 Million Equity Line of Credit Agreement
Q2
Notice of Late Filing for Quarterly Report
Q1
FY 2025
Notice of Late Filing for Annual Report
Q3
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
PRE 14A
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence